Click on the company or penalty amount for more information on each case. Click on the current parent name to reach the summary page for that parent company.
Company  | Current Parent | Current Parent Industry | Primary Offense Type | Year | Agency | Penalty Amount |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | fraud | 2005 | USAO | $300,000,000 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | off-label or unapproved promotion of medical products | 2016 | MULTI-AG | $19,500,000 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | price-fixing or anti-competitive practices | 2003 | MULTI-AG | $55,000,000 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | False Claims Act and related | 2008 | AL-AG | $11,000,000 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | False Claims Act and related | 2010 | PA-AG | $27,600,000 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | kickbacks and bribery | 2016 | CA-INS | $30,000,000 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | False Claims Act and related | 2021 | USAO | $75,000,000 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | price-fixing or anti-competitive practices | 2004 | private lawsuit-federal | $50,000,000 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | price-fixing or anti-competitive practices | 2022 | private lawsuit-federal | $10,800,000 |
| BRISTOL-MYERS SQUIBB | Bristol-Myers Squibb | pharmaceuticals | environmental violation | 2023 | MA-ENV | $11,615 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | air pollution violation | 2009 | EPA | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $2,328,154 |
| Bristol Myers Squibb Manufacturing Company | Bristol-Myers Squibb | pharmaceuticals | hazardous waste violation | 2008 | EPA | $52,000 |
| Bristol Myers Squibb Company | Bristol-Myers Squibb | pharmaceuticals | air pollution violation | 2008 | EPA | $66,770 |
| Bristol Myers Squibb Co. | Bristol-Myers Squibb | pharmaceuticals | False Claims Act and related | 2021 | MULTI-AG | $75,000,000 |
| BRISTOL MYERS SQUIBB CO | Bristol-Myers Squibb | pharmaceuticals | hazardous waste violation | 2005 | NJ-ENV | $12,000 |
| BRISTOL - MYERS SQUIBB MEDICAL IMAGING INC | Bristol-Myers Squibb | pharmaceuticals | air pollution violation | 2009 | EPA | $19,538 |
| Boehringer Ingleheim | Boehringer Ingelheim | pharmaceuticals | False Claims Act and related | 2011 | KS-AG | $1,400,000 |
| Boehringer Ingelheim Vetmedica, Inc. | Eli Lilly | pharmaceuticals | hazardous waste violation | 2012 | EPA | $68,475 |
| Boehringer Ingelheim Vetmedica, Inc. | Eli Lilly | pharmaceuticals | air pollution violation | 2011 | EPA | $300,000 |
| BOEHRINGER INGELHEIM VETMEDICA, INC | Eli Lilly | pharmaceuticals | air pollution violation | 2011 | EPA | $900,000 |
| BOEHRINGER INGELHEIM VETMEDICA, INC | Eli Lilly | pharmaceuticals | hazardous waste violation | 2012 | EPA | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $338,475 |
| Boehringer Ingelheim Roxane, Inc. et al. | Hikma Pharmaceuticals | pharmaceuticals | False Claims Act and related | 2009 | IA-AG | $357,000 |
| Boehringer Ingelheim Roxane, Inc. | Hikma Pharmaceuticals | pharmaceuticals | False Claims Act and related | 2008 | MA-AG | $1,800,000 |
| Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim Roxane, Inc., Roxane Laboratories, Inc. and Ben Venue Laboratories, Inc. | Boehringer Ingelheim | pharmaceuticals | False Claims Act and related | 2009 | KY-AG | $4,500,000 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Boehringer Ingelheim | pharmaceuticals | off-label or unapproved promotion of medical products | 2017 | MULTI-AG | $13,500,000 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Boehringer Ingelheim | pharmaceuticals | False Claims Act and related | 2010 | WI-AG | $7,750,000 |
| Boehringer Ingelheim Pharmaceuticals Inc. | Boehringer Ingelheim | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $95,000,000 |
| BOEHRINGER INGELHEIM PHARMACEUTICALS | Boehringer Ingelheim | pharmaceuticals | aviation safety violation | 2014 | FAA | $15,000 |
| Boehringer Ingelheim Pharmaceutical, Inc. | Boehringer Ingelheim | pharmaceuticals | labor relations violation | 2004 | NLRB | $50,000 |
| Boehringer Ingelheim Corp. | Boehringer Ingelheim | pharmaceuticals | False Claims Act and related | 2005 | TX-AG | $10,000,000 |
| Boehringer Ingelheim Animal Health USA Inc. | Boehringer Ingelheim | pharmaceuticals | employment discrimination | 2020 | OFCCP | $379,089 |
| Boehringer Ingelheim | Boehringer Ingelheim | pharmaceuticals | False Claims Act and related | 2012 | LA-AG | $3,250,000 |
| Biovail Corporation | Bausch Health | pharmaceuticals | accounting fraud or deficiencies | 2008 | SEC | $10,000,000 |
| BIOVAIL AMERICAS CORP. | Bausch Health | pharmaceuticals | benefit plan administrator violation | 2012 | EBSA | $10,001 |
| Biovail | Bausch Health | pharmaceuticals | False Claims Act and related | 2013 | LA-AG | $200,000 |
| Biogen, Inc. | Biogen | pharmaceuticals | False Claims Act and related | 2020 | DOJ_CIVIL | $22,000,000 |
| BIOGEN IDEC, INC. | Biogen | pharmaceuticals | workplace safety or health violation | 2014 | OSHA | $7,500 |
| Biogen Idec Inc. | Biogen | pharmaceuticals | consumer protection violation | 2007 | VT-AG | $10,000 |
| Biocryst Pharmaceuticals, Inc. | Biocryst Pharmaceuticals | pharmaceuticals | hazardous waste violation | 2014 | AL-ENV | $11,000 |
| BAXTER HEALTHCARE CORP DBA BAXTER BIOSCIENCE | Takeda Pharmaceutical | pharmaceuticals | workplace safety or health violation | 2011 | OSHA | $195,000 |
| Baxalta US, Inc. | Takeda Pharmaceutical | pharmaceuticals | air pollution violation | 2017 | CA-SCAQMD | $35,000 |
| Baxalta US Inc. | Takeda Pharmaceutical | pharmaceuticals | wage and hour violation | 2019 | private lawsuit-state | $4,750,000 |
| BAUSCH AND LOMB PHARMACEUTICALS, INC. | Bausch Health | pharmaceuticals | workplace safety or health violation | 2000 | OSHA | $7,000 |
| Bausch & Lomb Inc. | Bausch Health | pharmaceuticals | price-fixing or anti-competitive practices | 2020 | private lawsuit-federal | $10,000,000 |
| Bausch & Lomb | Bausch Health | pharmaceuticals | price-fixing or anti-competitive practices | 2001 | MULTI-AG | $17,500,000 |
| Barr Pharmaceuticals Inc. | Teva Pharmaceutical Industries | pharmaceuticals | price-fixing or anti-competitive practices | 2009 | private lawsuit-federal | $13,000,000 |
| Barr Pharmaceuticals Inc. | Teva Pharmaceutical Industries | pharmaceuticals | price-fixing or anti-competitive practices | 2007 | private lawsuit-federal | $4,150,000 |
| Barr Pharmaceuticals Inc. | Teva Pharmaceutical Industries | pharmaceuticals | price-fixing or anti-competitive practices | 2007 | private lawsuit-federal | $2,100,000 |
| Barr Pharmaceuticals | Teva Pharmaceutical Industries | pharmaceuticals | price-fixing or anti-competitive practices | 2008 | MULTI-AG | $5,900,000 |
| Barr Laboratories, Inc. and Duramed Pharmaceuticals, Inc. | Teva Pharmaceutical Industries | pharmaceuticals | False Claims Act and related | 2007 | MA-AG | $2,000,000 |
| BARR LABORATORIES, INC. | Teva Pharmaceutical Industries | pharmaceuticals | workplace safety or health violation | 2002 | OSHA | $14,000 |
| BARR LABORATORIES INC. | Teva Pharmaceutical Industries | pharmaceuticals | workplace safety or health violation | 2006 | OSHA | $65,250 |
| Aventis Pharmaceuticals, Inc. and Aventis Behring, LLC | Sanofi | pharmaceuticals | False Claims Act and related | 2012 | KY-AG | $2,290,000 |
| Aventis Pharmaceuticals, Inc. | Sanofi | pharmaceuticals | price-fixing or anti-competitive practices | 2012 | MULTI-AG | $1,650,000 |
| Aventis Pharmaceuticals Inc. | Sanofi | pharmaceuticals | False Claims Act and related | 2007 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $10,645,600 |
| Aventis Pharmaceuticals Inc. | Sanofi | pharmaceuticals | False Claims Act and related | 2010 | NJ-AG | $1,300,000 |
| Aventis Pharmaceuticals Inc. | Sanofi | pharmaceuticals | price-fixing or anti-competitive practices | 2013 | private lawsuit-federal | $800,000 |
| Aventis Pharmaceuticals Inc. | Sanofi | pharmaceuticals | price-fixing or anti-competitive practices | 2011 | private lawsuit-federal | $3,500,000 |
| Aventis Pharmaceuticals Inc. | Sanofi | pharmaceuticals | price-fixing or anti-competitive practices | 2011 | private lawsuit-federal | $9,615,384 |
| Aventis Pharmaceuticals Inc. | Sanofi | pharmaceuticals | price-fixing or anti-competitive practices | 2000 | private lawsuit-federal | $22,000,000 |
| Aventis Pharmaceuticals | Sanofi | pharmaceuticals | False Claims Act and related | 2019 | IL-AG | $14,708,388 |
| Aventis Pharmaceutical L.P. | Sanofi | pharmaceuticals | False Claims Act and related | 2009 | AL-AG | $14,833,333 |
| Aventis Pharmaceutical Inc. | Sanofi | pharmaceuticals | False Claims Act and related | 2009 | DOJ_CIVIL | $95,500,000 |
| Aventis Pharmaceutical Inc. | Sanofi | pharmaceuticals | False Claims Act and related | 2009 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $40,000,000 |
| Aventis | Sanofi | pharmaceuticals | False Claims Act and related | 2013 | LA-AG | $7,000,000 |
| ASTRAZENECA PLP | AstraZeneca | pharmaceuticals | environmental violation | 2021 | EPA | $18,960 |
| AstraZeneca PLC | AstraZeneca | pharmaceuticals | kickbacks and bribery | 2016 | SEC | $5,522,000 |
| AstraZeneca Pharmaceuticals, LP | AstraZeneca | pharmaceuticals | False Claims Act and related | 2010 | HI-AG | $3,333,333 |
| AstraZeneca Pharmaceuticals LP and AstraZeneca LP | AstraZeneca | pharmaceuticals | False Claims Act and related | 2011 | ID-AG | $2,500,000 |
| AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | False Claims Act and related | 2003 | DOJ_CIVIL | $354,900,000 |
| AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | False Claims Act and related | 2003 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $24,900,000 |
| AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | False Claims Act and related | 2009 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $2,600,000 |
| AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $218,092,993 |
| AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | price-fixing or anti-competitive practices | 2013 | private lawsuit-federal | $11,000,000 |
| AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | price-fixing or anti-competitive practices | 2012 | private lawsuit-federal | $20,000,000 |
| AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | price-fixing or anti-competitive practices | 2011 | private lawsuit-federal | $13,000,000 |
| AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | price-fixing or anti-competitive practices | 2011 | private lawsuit-federal | $90,000,000 |
| AstraZeneca Pharmaceuticals | AstraZeneca | pharmaceuticals | False Claims Act and related | 2009 | DOJ_CIVIL | $2,600,000 |
| AstraZeneca LP | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $520,000,000 |
| AstraZeneca LP | AstraZeneca | pharmaceuticals | False Claims Act and related | 2015 | DOJ_CIVIL | $46,500,000 |
| AstraZeneca LP | AstraZeneca | pharmaceuticals | False Claims Act and related | 2015 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $46,500,000 |
| AstraZeneca | AstraZeneca | pharmaceuticals | False Claims Act and related | 2004 | FL-AG | $807,826 |
| AstraZeneca | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | KY-AG | $5,500,000 |
| AstraZeneca | AstraZeneca | pharmaceuticals | consumer protection violation | 2010 | KY-AG | $5,391,000 |
| AstraZeneca | AstraZeneca | pharmaceuticals | False Claims Act and related | 2009 | KY-AG | $14,700,000 |
| AstraZeneca | AstraZeneca | pharmaceuticals | employment discrimination | 2021 | OFCCP | $560,000 |
| AstraZeneca | AstraZeneca | pharmaceuticals | price-fixing or anti-competitive practices | 2007 | private lawsuit-federal | $24,000,000 |
| Astellas Pharma US, Inc. | Astellas Pharma | pharmaceuticals | campaign finance violation | 2022 | FEC | $7,500 |
| Astellas Pharma US, Inc. | Astellas Pharma | pharmaceuticals | price-fixing or anti-competitive practices | 2016 | private lawsuit-federal | $13,250,000 |
| Astellas Pharma US Inc. | Astellas Pharma | pharmaceuticals | False Claims Act and related | 2019 | DOJ_CIVIL | $100,000,000 |
| Astellas | Astellas Pharma | pharmaceuticals | False Claims Act and related | 2013 | LA-AG | $1,130,000 |
| Apotex Corp. | Apotex Corp. | pharmaceuticals | price-fixing or anti-competitive practices | 2020 | DOJ_ANTITRUST | $24,100,000 |
| Apotex | Apotex Corp. | pharmaceuticals | False Claims Act and related | 2013 | LA-AG | $4,000,000 |
| ANIKA THERAPEUTICS INC. | Anika Therapeutics | pharmaceuticals | workplace safety or health violation | 2013 | OSHA | $5,800 |
| ANIKA THERAPEUTICS INC | Anika Therapeutics | pharmaceuticals | environmental violation | 2003 | MA-ENV | $15,500 |
| ANDRX PHARMACEUTICALS, INC. | Teva Pharmaceutical Industries | pharmaceuticals | hazardous waste violation | 2001 | FL-DEP | $15,000 |
| Anda | Teva Pharmaceutical Industries | pharmaceuticals | Controlled Substances Act violation | 2016 | WV-AG | $1,800,000 |
| Amyris, Inc. | Amyris | pharmaceuticals | investor protection violation | 2021 | SEC | $300,000 |
| AMRI Rensselaer, Inc. | Curia Inc. | pharmaceuticals | environmental violation | 2018 | NY-ENV | $21,250 |
| AMRI Rensselaer, Inc. | Curia Inc. | pharmaceuticals | environmental violation | 2014 | NY-ENV | $45,000 |
| Amphastar Pharmaceuticals, Inc. | Amphastar Pharmaceuticals | pharmaceuticals | price-fixing or anti-competitive practices | 2015 | MA-AG | $325,000 |
